10-K: Doximity Reports 13% Revenue Growth in FY2026

Doximity, Inc. announced its annual report for the fiscal year ended March 31, 2026, highlighting a 13% increase in revenue to $644.9 million and a net income of $196.1 million.

Summary

• Doximity, a leading physician-first tech company, reported revenue of $644.9 million for the fiscal year ended March 31, 2026, a 13% increase from the previous year.
• Net income for the fiscal year was $196.1 million, with diluted earnings per share at $0.98.
• The company's registered member base now exceeds 3 million, representing over 85% of U.S. physicians.
• Key financial metrics show adjusted EBITDA of $357.8 million and free cash flow of $317.5 million for the fiscal year.
• The company completed a $500 million share repurchase program and initiated a new one.
• Doximity also announced the acquisition of Pathway Medical Inc. to enhance its AI capabilities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as positive, reflecting continued revenue growth and strong profitability, despite increased operating expenses and ongoing legal matters.

Positives

• Revenue increased by 13% to $644.9 million for the fiscal year ended March 31, 2026.
• Net income was $196.1 million, demonstrating strong profitability.
• Adjusted EBITDA reached $357.8 million, with a consistent adjusted EBITDA margin of 55%.
• Free cash flow was robust at $317.5 million.
• Net revenue retention rate remained strong at 109%.
• The company continues to expand its network, with over 3 million registered members, covering more than 85% of U.S. physicians.
• Acquisition of Pathway Medical Inc. is expected to enhance AI capabilities.
• The company completed its previously authorized $500 million share repurchase program and initiated a new one.

Negatives

• Research and development expenses increased by 40% to $130.7 million, largely due to stock-based compensation.
• General and administrative expenses increased by 43% to $65.3 million, driven by legal fees and stock-based compensation.
• The company faces ongoing litigation, including a securities class action lawsuit and derivative lawsuits, with a settlement of $31 million agreed upon for the securities lawsuit.
• The company is subject to significant legal and regulatory risks, particularly concerning data privacy and AI usage.

Risks

• Failure to effectively manage growth could harm the business, financial condition, and results of operations.
• Increasing competition in the market for its solutions could lead to pricing pressure and loss of market share.
• Dependence on key customers for a significant portion of revenue poses a risk if one or more are lost.
• The development, deployment, and use of artificial intelligence may not achieve expected benefits and could create operational, reputational, regulatory, legal, and liability risks.
• The company is subject to stringent and changing laws, regulations, and standards related to privacy, data protection, and information security.
• The dual-class stock structure concentrates voting control, limiting the ability of other stockholders to influence corporate matters.
• Future sales and issuances of Class A common stock could result in dilution and depress the stock price.

Future Outlook

The company expects to continue investing in growing its business, which may lead to increased expenses and potentially lower margins in the near term. Future capital requirements will depend on revenue growth, customer payments, sales and marketing expansion, share repurchases, and R&D spending. Additional equity or debt financing may be required.

Management Comments

• Our mission is to help every physician be more productive and provide better care for their patients. We are physician-first, putting technology to work for doctors instead of the other way around.
• Our business model has delivered high revenue growth at scale with profitability.
• We believe that our existing cash and cash equivalents and marketable securities will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months.

Industry Context

StockSavvy.ai notes that Doximity's performance aligns with the growing trend of digital transformation in healthcare, leveraging AI to enhance physician productivity and streamline clinical workflows. The company's strong physician network and diversified revenue streams position it well within the competitive digital health landscape.

Management Changes

Legal Proceedings

• Securities lawsuit alleging misrepresentation of user count and engagement rates; settlement of $31 million agreed upon, subject to court approval.
• Six shareholder derivative lawsuits asserting claims for violations of securities laws, breach of fiduciary duties, and mismanagement.
• Lawsuit filed by OpenEvidence Inc. alleging unauthorized access to its AI medical information platform, with counterclaims filed by Doximity for false advertising and defamation.

Stakeholder Impact

• Shareholders benefit from continued revenue growth and profitability, though potential dilution from future stock issuances is a consideration.
• Employees may benefit from equity awards and the company's growth, but face increased R&D and G&A expenses.
• Customers (pharmaceutical manufacturers and health systems) continue to receive access to a large physician network for marketing and hiring.
• Patients may benefit from improved physician productivity and workflow tools.

Next Steps

• Continue to grow the Doximity Network by expanding offerings to other medical professionals.
• Continuously improve and innovate on the platform, including AI capabilities.
• Expand within existing customers by increasing usage across more brands and service lines.
• Attract new customers in the pharmaceutical and health system sectors.
• Further monetize Workflow Solutions and grow patient-facing tools.
• Consider strategic acquisitions to expand platform capabilities.

Key Dates

Recommendation

Doximity demonstrates consistent revenue growth and strong profitability, supported by a dominant physician network and expanding AI capabilities. However, the significant increase in operating expenses, particularly in R&D and G&A, coupled with ongoing litigation and the inherent risks of the rapidly evolving digital health and AI sectors, warrant a cautious 'hold' rating. Investors should monitor the impact of increased investments and legal outcomes on future performance.

Keywords

Doximity, SEC Filing, 10-K, Annual Report, Healthcare Technology, Physician Network, Digital Health, AI in Healthcare, Marketing Solutions, Hiring Solutions, Workflow Solutions, Financial Results